The Drug Hunter’s Assistant: Accelerating Drug Discovery With AI
Are The High Expectations Justified?
The hype around Artificial Intelligence has been deafening in recent years, but real progress can only come when drug discovery culture and regulators catch up with the technology.
You may also be interested in...
Focusing too much on the US provides a blinkered view of the industry and prevents access to the myriad opportunities on offer globally.
US major continues its expansion in oncology with an early stage deal with Flagship Pioneering protegés.
The Bayesian adaptive trial design is looking to slash development times, starting with a Phase II trial of Ridgeback’s drug, a potential challenger to Gilead’s remdesivir.